MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-11-2026
Harrow Health Total Current Liabilities 2011-2026 | HROW
Annual Total Current Liabilities Harrow Health
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 96.3 M | 91.3 M | 49.3 M | 18.6 M | 9.72 M | 10.8 M | 12.3 M | 11.9 M | 5.77 M | 9.9 M | 5.37 M | 1.56 M | 651 K | 710 K | 1.86 M | 335 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 96.3 M | 335 K | 20.4 M |
Total Current Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cumberland Pharmaceuticals
CPIX
|
36.7 M | $ 5.87 | 6.53 % | $ 87.2 M |  USA |
 |
Endo International plc
ENDP
|
539 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
10.4 M | - | - | $ 36.6 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
3.81 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
7.71 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
11.4 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
125 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
20.8 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
21.9 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
48.2 M | $ 2.74 | 0.37 % | $ 1.05 B |  Canada |
 |
Athenex
ATNX
|
115 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
48.8 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
1.03 B | - | - | $ 11.5 B | USA |
 |
Organogenesis Holdings
ORGO
|
100 M | $ 2.66 | - | $ 337 M | USA |
 |
Pacira BioSciences
PCRX
|
310 M | $ 23.35 | -0.55 % | $ 1.08 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
111 M | - | -39.89 % | $ 27.7 M | USA |
 |
Bausch Health Companies
BHC
|
4.18 B | $ 5.47 | 0.37 % | $ 2.03 B | Canada |
 |
Canopy Growth Corporation
CGC
|
94.4 M | $ 1.04 | -2.8 % | $ 112 M | Canada |
 |
Solid Biosciences
SLDB
|
33.5 M | $ 6.62 | 1.85 % | $ 579 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
4.1 M | $ 1.1 | 3.77 % | $ 1.37 M | USA |
 |
Jupiter Wellness
JUPW
|
5.98 M | - | - | $ 33.6 M | USA |
 |
Tilray
TLRY
|
433 M | $ 5.29 | -3.11 % | $ 3.27 B | Canada |
 |
Lannett Company
LCI
|
105 M | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
75.3 M | $ 6.09 | -5.58 % | $ 393 M | USA |
 |
Emergent BioSolutions
EBS
|
132 M | $ 8.45 | 0.96 % | $ 452 M | USA |
 |
Veru
VERU
|
7.79 M | $ 2.35 | 5.86 % | $ 34.4 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
16.4 M | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
128 M | $ 23.44 | 0.3 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
16.1 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
94.8 M | - | - | $ 1.42 B | USA |
 |
cbdMD
YCBD
|
3.19 M | $ 0.76 | -2.32 % | $ 3.06 M | USA |
 |
PetIQ
PETQ
|
190 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
6.43 M | $ 7.04 | -2.36 % | $ 278 M | USA |
 |
Recro Pharma
REPH
|
50 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
177 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
5.73 M | $ 0.73 | 3.0 % | $ 36.5 M | USA |
 |
PLx Pharma
PLXP
|
11.9 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
7.09 B | $ 16.65 | 1.15 % | $ 19.4 B | USA |
 |
Zomedica Corp.
ZOM
|
9.45 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
9.17 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
9.58 M | $ 0.79 | -2.06 % | $ 28.4 M | USA |
 |
Tricida
TCDA
|
29.5 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
7.4 M | $ 0.76 | -0.29 % | $ 3.26 M |  China |
 |
TherapeuticsMD
TXMD
|
4.78 M | $ 2.12 | 0.47 % | $ 24.5 M | USA |